Shire acquires VC-backed Lumena Pharmaceuticals

By Iris Dorbian — 2 years ago

Shire has acquired Lumena Pharmaceuticals. No financial terms were disclosed. Citi provided financial advice to Lumena. Based in San Diego, Lumena is a biopharmaceutical company focused on rare cholestatic liver diseases and serious metabolic disorders. Its backers include New Enterprise Associates, Adage Capital Management, RA Capital Management, Pappas Ventures, RiverVest Venture Partners and Alta Partners.

Continue

VC-backed Genocea Biosciences hires new CFO

By Iris Dorbian — 2 years ago

Genocea Biosciences said Monday that it has named Jonathan Poole as chief financial officer. Previously, Poole worked at Shire where he served as senior vice president of finance for pipeline and technical operations. Based in Cambridge, Mass., Genocea Biosciences is a developer of T-cell vaccines. Genocea’s backers include Polaris Venture Partners, Lux Ventures, Skyline Ventures, Auriga Ventures, The Bill & Melinda Gates Foundation and Morningside Ventures.

Continue

Promethera Biosciences Raises $31.4m in Series B

By Angela Sormani — 4 years ago

Belgian cell therapy company Promethera Biosciences, has raised 23.6 million euros ($31.4 million) in Series B round of investment. Among the new investors are the venture arms of Boehringer Ingelheim and Shire, Japanese investment fund Mitsui Global Investment, US company ATMI and Belgian venture capital fund Sambrinvest. PRESS RELEASE Promethera Biosciences, the Belgian cell therapy […]

Continue

NeuroPhage Raises $9M in Series B-1

By Staff Report — 4 years ago

NeuroPhage Pharmaceuticals Inc., a Cambridge, Mass.-based biotech company, has raised $9 million in a Series B-1 round of financing. The round was completed by existing investors, including Merieux Developpement, Shire, and undisclosed private investors. The company has raised a total of $28.6 million since its inception in 2006. PRESS RELEASE NeuroPhage Pharmaceuticals, Inc. (NeuroPhage), a […]

Continue

DBV Technologies Adds $25.5 Million in Series C

5 years ago

Paris-based biotech company DBV Technologies has raised 19.4 million euros ($25.5 million) in a Series C round led by new investors InnoBio Fund and Lundbeckfond Ventures. Shire plc, ALTO Invest, Sofinnova Partners and ALK Abello also contributed to the round. DBV Technologies is developing products to combat food allergies such as peanut and milk. The company’s previous investors include Apax Partners, among others.

Continue